Nextwave Drug Patent Portfolio
Nextwave owns 1 orange book drug protected by 7 US patents Given below is the list of Nextwave's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
US8465765 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
US8563033 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
US8778390 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
US8956649 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
US9040083 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
US8062667 | Modified release formulations containing drug-ion exchange resin complexes | 29 Mar, 2029 | Active |
Latest Legal Activities on Nextwave's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nextwave.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2024 | US8287903 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2022 | US9040083 |
Payment of Maintenance Fee, 8th Year, Large Entity | 29 Dec, 2021 | US8778390 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 07 Apr, 2021 | US8563033 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 01 Oct, 2020 | US8465765 |
Payment of Maintenance Fee, 8th Year, Large Entity | 02 Apr, 2020 | US8287903 (Litigated) |
Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2018 | US9040083 |
Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jan, 2018 | US8778390 (Litigated) |
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US8778390 (Litigated) |
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US8563033 (Litigated) |
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US9040083 |
Recordation of Patent Grant Mailed
Critical
| 26 May, 2015 | US9040083 |
Patent Issue Date Used in PTA Calculation
Critical
| 26 May, 2015 | US9040083 |
Email Notification
Critical
| 07 May, 2015 | US9040083 |
Issue Notification Mailed
Critical
| 06 May, 2015 | US9040083 |
Nextwave's Family Patents
Nextwave Drug List
Given below is the complete list of Nextwave's drugs and the patents protecting them.
1. Quillivant Xr
Quillivant Xr is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(6 years from now)
| Active |
US8465765 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(6 years from now)
| Active |
US8563033 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(6 years from now)
| Active |
US8778390 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(6 years from now)
| Active |
US8956649 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(6 years from now)
| Active |
US9040083 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(6 years from now)
| Active |
US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
29 Mar, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quillivant Xr's drug page